Richard Haas's Insider Trades & SAST Disclosures
Richard Haas's most recent trade in Myriad Genetics, Inc. was a trade of 4,493 Common Stock done at an average price of $10.0 . Disclosure was reported to the exchange on March 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard Haas.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 4,493 | 181,536 (0%) | 0% | 10.0 | 44,975 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,724 | 178,635 (0%) | 0% | 10.0 | 17,206 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 1,694 | 186,029 (0%) | 0% | 10.0 | 16,957 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 1,177 | 180,359 (0%) | 0% | 10.0 | 11,746 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 54,124 | 195,448 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 4,390 | 191,058 (0%) | 0% | 10.1 | 44,207 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 13 Mar 2025 | 3,335 | 187,723 (0%) | 0% | 10.1 | 33,583 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.74 per share. | 25 Feb 2025 | 1,016 | 128,566 (0%) | 0% | 11.7 | 11,928 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 12,758 | 141,324 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.37 per share. | 09 Oct 2024 | 2,515 | 129,582 (0%) | 0% | 24.4 | 61,291 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,718 | 132,097 (0%) | 0% | 22.2 | 38,208 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,685 | 134,987 (0%) | 0% | 22.2 | 37,474 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.24 per share. | 22 Mar 2024 | 1,172 | 133,815 (0%) | 0% | 22.2 | 26,065 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 35,178 | 139,978 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 14 Mar 2024 | 3,306 | 136,672 (0%) | 0% | 21.2 | 69,955 | Common Stock |
| Myriad Genetics, Inc. | Haas Kevin Richard | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 25 Feb 2024 | 881 | 104,800 (0%) | 0% | 22.7 | 20,016 | Common Stock |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 1,014 | 60,381 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,943 | 59,367 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 1,218 | 53,424 | - | - | Deferred Stock Units | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,674 | 108,249 (0%) | 0% | 23.7 | 39,707 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.72 per share. | 24 Mar 2023 | 1,142 | 109,923 (0%) | 0% | 23.7 | 27,088 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.91 per share. | 22 Mar 2023 | 1,677 | 111,065 (0%) | 0% | 22.9 | 38,420 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 28,459 | 112,742 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.54 per share. | 25 Feb 2023 | 1,012 | 84,283 (0%) | 0% | 18.5 | 18,762 | Common Stock |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 922 | 52,206 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 899 | 51,284 | - | - | Deferred Stock Units | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.62 per share. | 09 Oct 2022 | 1,721 | 85,295 (0%) | 0% | 19.6 | 33,766 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.41 per share. | 25 Sep 2022 | 862 | 87,016 (0%) | 0% | 18.4 | 15,869 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.69 per share. | 25 Sep 2022 | 346 | 87,878 (0%) | 0% | 18.7 | 6,467 | Common Stock |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 880 | 50,385 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,836 | 49,505 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 1,084 | 44,669 | - | - | Deferred Stock Units | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.69 per share. | 22 Apr 2022 | 467 | 26,235 (0%) | 0% | 44.7 | 20,870 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,689 | 88,224 (0%) | 0% | 25.3 | 42,765 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.32 per share. | 24 Mar 2022 | 1,153 | 89,913 (0%) | 0% | 25.3 | 29,194 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 19,238 | 91,066 (0%) | 0% | 0 | Common Stock | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.98 per share. | 17 Mar 2022 | 2,833 | 26,702 (0%) | 0% | 47.0 | 133,094 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2022 | 1,738 | 29,535 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.69 per share. | 25 Feb 2022 | 865 | 71,828 (0%) | 0% | 24.7 | 21,357 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 4,300 | 29,231 (0%) | 0% | 0 | Common Stock | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.87 per share. | 17 Feb 2022 | 1,434 | 27,797 (0%) | 0% | 42.9 | 61,476 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 19,520 | 72,693 (0%) | 0% | 0 | Common Stock | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 919 | 43,585 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 729 | 42,666 | - | - | Deferred Stock Units | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.88 per share. | 09 Oct 2021 | 1,729 | 53,173 (0%) | 0% | 30.9 | 53,392 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 865 | 54,902 (0%) | 0% | 33.3 | 28,813 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.31 per share. | 25 Sep 2021 | 346 | 55,767 (0%) | 0% | 33.3 | 11,525 | Common Stock |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 718 | 41,937 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 3,614 | 41,219 | - | - | Deferred Stock Units | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 15.86 per share. | 28 May 2021 | 344 | 56,113 (0%) | 0% | 15.9 | 5,456 | Common Stock |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 748 | 37,605 | - | - | Deferred Stock Units | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 44.26 per share. | 07 May 2021 | 5,000 | 24,931 (0%) | 0% | 44.3 | 221,310 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2021 | 3,556 | 29,931 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Kevin Richard Haas | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 13,326 | 55,769 (0%) | 0% | 0 | Common Stock | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.61 per share. | 15 Mar 2021 | 374 | 26,375 (0%) | 0% | 39.6 | 14,814 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.92 per share. | 10 Mar 2021 | 1,179 | 26,749 (0%) | 0% | 39.9 | 47,066 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 9,265 | 30,926 (0%) | 0% | 0 | Common Stock | |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.03 per share. | 08 Mar 2021 | 2,998 | 27,928 (0%) | 0% | 40.0 | 120,010 | Common Stock |
| ODP Corporation (The) | Richard Haas | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.88 per share. | 05 Mar 2021 | 381 | 21,661 (0%) | 0% | 37.9 | 14,432 | Common Stock |
| Myriad Genetics, Inc. | Kevin Richard Haas | SVP Technology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 10,000 | 42,443 (0%) | 0% | 0 | Common Stock | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 832 | 36,857 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Nov 2020 | 943 | 36,025 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2020 | 1,084 | 35,082 | - | - | Deferred Stock Units | |
| Lazard Ltd. - Ordinary Sha... | Richard N. Haass | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2020 | 6,348 | 33,998 | - | - | Deferred Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges